Conscious Source: Cartography of Psychedelics, Well-being & Consciousness

Support the research, education, and awareness of psychedelic-based therapies and their role in raising wellbeing and exploring consciousness.

Who we are?

About Conscious Source

Our goal is to expand into role of psychedelics for wellbeing and expansion on consciousness and human thriving

The Chopra Foundation has launched the Conciou(S)ource – Cartography of Psychedelics, Well-being & Consciousness Initiative to support the research, education and awareness of psychedelic based therapies and their role in raising wellbeing and exploring consciousness.

The goal of this initiative is to build on the existing strong industry research and expand into role of psychedelics for wellbeing and expansion on consciousness and human thriving. The Chopra Foundation Initiative will focus on how psychedelics affect behavior, mood, cognition, brain function, biological markers of health and exploration of consciousness.

The Chopra Foundation is working closely with industry partners such as Cybin to support education and awareness about Cybin’s ground-breaking research to harness the potential of psychedelic-based therapies to support mental health. Cybin is currently advancing multiple clinical programs evaluating its investigational psychedelic therapeutics to potentially treat depression, alcohol use disorder, and anxiety disorders. Most recently, Cybin received FDA IND clearance for its Phase 1/2a clinical trial evaluating its psilocybin analog for major depressive disorder.

Become a Sponsor of Conscious Source

Cartography of Psychedelics, Well-being & Consciousness

Cybin

What does Cybin do?

Mission is to revolutionize mental healthcare

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues.

The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Watch Video